Sinovac CEO Weidong Yin On China’s Evolving Vaccine Market: An Interview With PharmAsia News

Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.